Percutaneous coronary artery revascularization procedures in pediatric heart transplant recipients: A large single center experience

被引:6
|
作者
Turner, Mariel E. [1 ]
Addonizio, Linda J. [1 ]
Richmond, Marc E. [1 ]
Zuckerman, Warren A. [1 ]
Vincent, Julie A. [1 ]
Torres, Alejandro J. [1 ]
Collins, Michael B. [2 ]
机构
[1] Columbia Univ, Coll Phys & Surg, Div Pediat Cardiol, 3959 Broadway,2 North, New York, NY 10032 USA
[2] Columbia Univ, Coll Phys & Surg, Div Cardiol, New York, NY USA
关键词
percutaneous coronary intervention; cardiac allograft vasculopathy; pediatric intervention; heart transplantation; CARDIAC ALLOGRAFT VASCULOPATHY; INTERVENTIONS; DISEASE; STENTS;
D O I
10.1002/ccd.26544
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo describe our experience, at a large pediatric heart transplant center, with percutaneous coronary interventions (PCI) for cardiac allograft vasculopathy (CAV). Background: CAV is a leading cause of late graft failure, mortality, and re-transplantation in pediatric heart transplant (HTx) recipients. Studies of PCI in adult patients have shown some short-term improvements, but no significant change in long-term outcomes. There are limited data on PCI for CAV in pediatric patients. We describe the largest single-center experience to date. Methods: We performed a retrospective chart review of all pediatric HTx recipients who underwent PCI for a diagnosis of CAV from 2005 to 2014. Results: Twenty-three procedures were performed in 13 patients, at a median age of 16.4 years (range 5.6-21.2) and median time from HTx to first PCI of 8.3 years (range 2.9-20.3). Three cases consisted of angioplasty alone, two cases had bare metal stents implanted, and the remaining 18 had drug-eluting stents implanted. There was acute procedural success in all but one case, and there was only one procedure-related complication (rebleeding from access site). During the follow-up interval (median 10.4 months, range 0.2-111.8), 7/13 patients had repeat PCI performed, two patients died (at 1.8 and 5.8 months post-PCI), and five were re-transplanted (range 0.2-18 months post-PCI). Freedom from death or retransplant by Kaplan-Meier analysis was 54% at 1 year. Conclusions: PCI can be performed safely and effectively in pediatric HTx recipients with CAV. Similar to the adult experience, there remains a high rate of disease progression and graft failure. (c) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:797 / 803
页数:7
相关论文
共 50 条
  • [1] Outcomes after Percutaneous Coronary Artery Revascularization Procedures for Allograft Vasculopathy in Pediatric Heart Transplant Recipients: A Multi-Institutional Experience
    Jeewa, A.
    Chin, C.
    Pahl, E.
    Atz, A. M.
    Carboni, M. P.
    Tresler, M. A.
    Naftel, D. C.
    Rodriguez, R. J.
    Allain-Rooney, T.
    Dipchand, A. I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S133 - S133
  • [2] OUTCOMES AFTER CORONARY ARTERY REVASCULARIZATION PROCEDURES FOR ALLOGRAFT VASCULOPATHY IN PEDIATRIC HEART TRANSPLANT RECIPIENTS.
    Jeewa, Aamir
    Chin, Clifford
    Pahl, Elfriede
    Atz, Andrew M.
    Carboni, Michael P.
    Tresler, Margaret A.
    Naftel, David C.
    Rodriguez, Rose J.
    Allain-Rooney, Tina
    Dipchand, Anne I.
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 53 - 53
  • [3] Outcomes after percutaneous coronary artery revascularization procedures for cardiac allograft vasculopathy in pediatric heart transplant recipients: A multi-institutional study
    Jeewa, Aamir
    Chin, Clifford
    Pahl, Elfriede
    Atz, Andrew M.
    Carboni, Michael. P.
    Pruitt, Elizabeth
    Naftel, David C.
    Rodriguez, Rose
    Dipchand, Anne I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (09): : 1163 - 1168
  • [4] Percutaneous coronary revascularization in coronary artery disease: Lessons from a single center experience
    Aksoy, Olcay
    Tuzcu, E. Murat
    Ellis, Stephen G.
    Whitlow, Patrick L.
    Cam, Akin
    Batizy, Lillian
    Agarwal, Shikhar
    Franco, Irving
    Bajzer, Christopher
    Simpfendorfer, Conrad
    Raymond, Russell
    Nair, Ravi
    Cho, Leslie
    Shishehbor, Mehdi H.
    Lincoff, A. Michael
    Kapadia, Samir R.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 81 (01) : E1 - E8
  • [5] Transplant coronary artery disease in pediatric heart transplant recipients
    Dent, CL
    Canter, CE
    Hirsch, R
    Balzer, DT
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (03): : 240 - 248
  • [6] Percutaneous coronary interventions in heart trasplant recipients: a single-center experience
    Colombo, P.
    Sacco, A.
    Bruschi, G.
    Bossi, I.
    Turazza, F.
    Frigerio, M.
    Klugmann, S.
    EUROPEAN HEART JOURNAL, 2008, 29 : 778 - 778
  • [7] Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience
    Chen, Teaghan T.
    Greene, Megan M.
    Everitt, Melanie D.
    Simpson, Kathleen E.
    PEDIATRIC TRANSPLANTATION, 2023, 27 (02)
  • [8] Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience
    Lobach, NE
    Pollock-BarZiv, SM
    West, LJ
    Dipchand, AI
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : 184 - 189
  • [9] Mycophenolate mofetil in pediatric heart transplant recipients: A single-center experience
    Dipchand, AI
    Benson, L
    McCrindle, BW
    Coles, J
    West, L
    PEDIATRIC TRANSPLANTATION, 2001, 5 (02) : 112 - 118
  • [10] Long-Term Outcomes of Percutaneous Coronary Intervention in Transplant Coronary Artery Disease in Pediatric Heart Transplant Recipients
    Lee, Michael S.
    Sachdeva, Ritu
    Kim, Moo Hyun
    Sachdeva, Rajesh
    JOURNAL OF INVASIVE CARDIOLOGY, 2012, 24 (06): : 278 - 281